Skip to the content
Know your tech before you buy it. Makers: get listed from $49/mo

Benevolent Platform

benevolent.com

5.5 Club score Visit benevolent.com

What the maker publishes

AI and data
BenevolentAI describes its technology as using multimodal data to surface insights and accelerate biomedical discovery. source
Audience
BenevolentAI says its team supports scientists and executives using AI and machine learning in their work. source
Collaborations
The company names AstraZeneca and Merck among its pharmaceutical discovery collaboration partners. source
Contact
The company provides a press contact email address. source
Drug discovery
The company says it uses its platform, scientific expertise, and wet-lab facilities to accelerate novel drug discovery. source
Focus
In April 2024, BenevolentAI said it would focus on drug discovery collaborations and its proprietary pipeline. source
Founded
2013 source
Founded
BenevolentAI's press kit lists 2013 as its founding year. source
Headquarters
London, UK source
Headquarters
The company describes itself as headquartered in London. source
Knowledge Exploration Tools
The company announced that work on its Knowledge Exploration Tools would cease after a market assessment. source
Knowledge graph
The company says its technology builds on investment in a knowledge graph and proprietary ontologies. source
Platform development
A 2024 company announcement stated that investment would continue in development of the BenevolentAI Platform. source
Platform offering
BenevolentAI describes its platform as integrating AI and science to uncover new biology, predict novel targets, and develop drugs for complex diseases. source
Product availability
The current homepage presents Qor as an always-on strategic function for biopharma decision makers and life science consultancies. source

Checked against the maker's pages on 14 Nov 2026.